FirstPoint and FirstDoc Application of the DIA EDM Reference Model

Slides:



Advertisements
Similar presentations
Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.
Advertisements

Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
TC3 Meeting in Montreal (Montreal/Secretariat)6 page 1 of 10 Structure and purpose of IEC ISO - IEC Specifications for Document Management.
GPS 2011 Slide - 1 COMPETITIVE STRATEGIES APAC Discussion.
The Correct e- Mixtures (A fully validated EHR, the way forward) Brendan Delaney Guy’s and St Thomas’ Charity Chair in Primary Care Research.
FDA’s Biosimilars Guidance -- Legal and Regulatory Considerations James S. Cohen, Esq. McDermott Will & Emery DIA Webinar April 10, 2012.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.
Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.
1 Optimal Strategies for Preparing Integrated and Clinical Summaries for a New Drug Application: Making it Work Under Any Circumstance Lisa A. Pierchala,
Bayesian approach to equivalence study of medical device 1 1.
Sherri de Coronado Enterprise Vocabulary Services NCI Center for Bioinformatics and Information Technology March 11, 2009 A Terminology.
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim.
Making Comments Count for High-Impact Regulations and Guidelines in the US Virginia (Ginny) Beakes-Read Executive Director, Global Regulatory Policy and.
Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.
Microsoft Virtual Academy Jamie McAllister | SharePoint MVP & Solution Architect Rob Latino | Program Manager in Office 365 Support.
Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.
Meredith Brown-Tuttle, RAC Director APT Pharmaceuticals, Inc.
DIA Trial Master File Reference Model
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.
User Survey Responses: EDM Reference Model for Regulatory Submissions Antoinette Azevedo e-SubmissionsSolutions.com Core Team Member User Survey Co-Designer.
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.
Global Staffing Solutions With a Local Flavor Mary Painter, Senior Account Manager June 25, 2012 The information contained in this communication is confidential.
Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &
Copyright © Trinetra Wireless
Gabor Fari Life Sciences Solution Strategist Microsoft Corporation
Session Title Date ǀ Time
- A “Portable” Implementation
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Verizon Business Net Conferencing
Presenter Title Organization
Track 11 Symposium 27 June :30 – 3:00 PM
Clinical Trial Disclosure:
Perspective on GCP Warning Letters
Molly Butler Auditor II Quality Associates, Inc.
PROGRAM / PROCESS GUIDE MAY 2017
Interactive Session: Presentation of Scenarios and Q&A
OGSA Service Classifications
Community-Based and Cluster-Randomized Studies –‘Pragmatic’ Approaches for Life Cycle Evidence? Florian Eichmann, PhD Principal Scientific Affairs and.
Customize Office 365 Search and create result sources
Presenter Name Title Organization.
Why the Industry Needs an EDM Reference Model
‘Accessing Emerald’ Saudi Digital Library
Parallelspace PowerPoint Template for ArchiMate® 2.1 version 2.0
Dell EMC Distribution Coverage Strategy for Storage
Dell EMC Distribution Coverage Strategy for Storage
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
Release Summary Skybox® Risk Control 6.0 New KPI and Metrics to Analyze and Prioritize the Most Critical Risks Skybox Risk Control Overview Skybox Risk.
SharePoint Designer 2010: Top 10 Things To Know
PMI® Leadership Institute Meeting 2018―EMEA
International Cooperation
PMI® EMEA Congress 2018 Session Title Session Date | Time
Presenter Name Title Organization.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
1 Session Title 2 line 3 line 4 line
ATTN Presenters – please review and remove this slide from your PowerPoint deck before uploading.
Session Title Date ǀ Time
SharePoint Foundation 2010
1 Session Title 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
William W. Gregory for the CIOMS MLG Exploratory Team Pfizer Inc
SESSION TITLE Session # <insert number here> Date Month Year
SESSION TITLE Session #<insert number here> Date Month Year
Presentation transcript:

FirstPoint and FirstDoc Application of the DIA EDM Reference Model Jennifer Wemstrom, Principal, Solution Specialist CSC Life Sciences February 11, 2009

Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated.   These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. Change to: In addition to DIA’s continued presence in North America, Europe, and Japan, DIA also serves the following regions: India (remove italics from Mumbai, India, October 16-18, 2006) Middle East (7th Annual Middle East Regulatory Conference, Dubai, UNITED ARAB EMIRATES, November 14-16, 2006) China Remove Central and Eastern Europe since it’s referenced at the top. Latin America 2

CSC’s EDM Products FirstDoc FirstPoint Based on EMC’s Documentum Platform FirstPoint Based on Microsoft’s SharePoint Platform Both applications are preconfigured with CSC’s “Best Practices” for Life Sciences which are analogous to the EDM Reference Model

Best Practices History CSC Best Practices developed over a decade of over 45 implementations Most recently in the last 2-3 years, several clients contributed directly to the revising of the Best Practices model Abbott, sanofi-aventis, Schering-Plough, Gilead, Amgen, Baxter, Takeda The commonalities of their implementations were built back into the model Model has been “road tested” with numerous implementations, has reduced analysis timelines and proven successful with business users in production

Best Practices vs. EDM Reference Model A high level analysis shows the models very well aligned in both products FirstDoc/DCTM EDM Reference Model CSC Best Practices Domain Document Type Group Document Subtype Artifact Document Unit FirstPoint/MSFT EDM Reference Model CSC Best Practices Domain Library Group Content Type Artifact Document Type

Best Practices vs. EDM Reference Model A detailed analysis also shows models very closely aligned Clinical: Nearly identical Nonclinical: Nearly identical except optional properties of Study Director and Study Facility CMC (Quality): Nearly identical except optional property of Impurity Regulatory Administrative: Similar but slightly different approach which contains a single global model encompassing US, EU, Japan, Canada and Australia

Best Practices vs. EDM Reference Model While the artifacts are almost identical in each domain, CSC’s best practices model has more granular Groups than the EMD Reference Model This is so that different properties can be applied at the Group level. For example, a Study Protocol is a different document Group than a Study Report. This is so that an EU Protocol can have a EUDACT #, while a Study Report can have a Type of Report such as Interim, Final, etc. In all cases, the CSC Best Practices Model contains all the artifacts, properties, and valid values recommended by the EDM Reference Model and contains additional properties Clients can choose to not use additional properties if desired CSC’s model contains a TMF Domain, and is offered in two “flavors” one combined with Clinical and one stand alone

FD & FP Value Add Using the EDM Reference Model Highly configurable solutions that can adapt to changes in the model or client requested changes Product Dictionaries and Guided Paths which relate and filter controlled values and client specific metadata based on user input Security models based on Reference Model Metadata Preconfigured property mapping with industry leading publishing vendors for auto eCTD Outline creation Dynamic Views tailored to user preferences using both artifacts and metadata

Detailed Documentation CSC Best Practices EDM Reference Model

Future Steps Implement property changes to align exactly with Reference Model Add optional EMD Reference Model properties not in CSC BP Add optional “Group” property to map where Groups and Subtypes do exactly not align Targeted for FirstDoc R&D 6.1 and FirstPoint 2.0 Implement Pharmacovigilance Model Implement Labeling Model CSC has internal draft model targeted for FirstDoc 6.1 release and FirstPoint 2.0 release but will look to align EDM Reference Labeling Model when released CSC’s Labeling Focus Group Active participation in the DIA EDM Reference Model working group